Addendum
Concizumab (haemophilia B) – Addendum to Project A25-56
Report documents
-
Addendum
Concizumab (haemophilia B) Addendum to Project A25-56
Dossier assessment
Indication:
Routine prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency) and factor IX inhibitors and of 12 years of age or more
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
16-10-2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-115
- Commission
- Commission awarded on 09.09.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-115_en
Connected Projects
-
Dossier assessment
Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed